TD Asset Management Inc Sells 6,800 Shares of Apogee Therapeutics Inc. $APGE

TD Asset Management Inc lowered its holdings in Apogee Therapeutics Inc. (NASDAQ:APGE) by 6.7% in the 2nd quarter, according to the company in its most recent filing with the Securities and Exchange Commission. The firm owned 94,588 shares of the company’s stock after selling 6,800 shares during the quarter. TD Asset Management Inc’s holdings in Apogee Therapeutics were worth $4,108,000 at the end of the most recent quarter.

Several other hedge funds have also bought and sold shares of the business. Mirae Asset Global Investments Co. Ltd. grew its position in Apogee Therapeutics by 18.0% in the 2nd quarter. Mirae Asset Global Investments Co. Ltd. now owns 1,779 shares of the company’s stock valued at $77,000 after purchasing an additional 272 shares during the period. MIRAE ASSET GLOBAL ETFS HOLDINGS Ltd. grew its position in Apogee Therapeutics by 2.9% in the 1st quarter. MIRAE ASSET GLOBAL ETFS HOLDINGS Ltd. now owns 24,529 shares of the company’s stock valued at $921,000 after purchasing an additional 694 shares during the period. Brooklyn Investment Group acquired a new stake in Apogee Therapeutics in the 1st quarter valued at $42,000. AlphaQuest LLC acquired a new stake in Apogee Therapeutics in the 1st quarter valued at $43,000. Finally, Rhumbline Advisers grew its position in Apogee Therapeutics by 3.2% in the 1st quarter. Rhumbline Advisers now owns 54,385 shares of the company’s stock valued at $2,032,000 after purchasing an additional 1,665 shares during the period. Institutional investors and hedge funds own 79.04% of the company’s stock.

Analyst Upgrades and Downgrades

Several research firms recently issued reports on APGE. Weiss Ratings reissued a “sell (d-)” rating on shares of Apogee Therapeutics in a research report on Wednesday, October 8th. Wedbush reissued an “outperform” rating and issued a $90.00 price target on shares of Apogee Therapeutics in a research report on Monday, August 11th. Bank of America lifted their price target on shares of Apogee Therapeutics from $78.00 to $87.00 and gave the company a “buy” rating in a research report on Thursday, August 28th. BTIG Research reiterated a “buy” rating and issued a $115.00 target price on shares of Apogee Therapeutics in a research note on Thursday, October 9th. Finally, Citigroup reiterated a “buy” rating on shares of Apogee Therapeutics in a research note on Thursday, August 28th. Eight investment analysts have rated the stock with a Buy rating, one has given a Hold rating and one has assigned a Sell rating to the stock. According to data from MarketBeat.com, the stock has a consensus rating of “Moderate Buy” and an average price target of $92.63.

Apogee Therapeutics Price Performance

NASDAQ APGE opened at $56.94 on Tuesday. Apogee Therapeutics Inc. has a 1 year low of $26.20 and a 1 year high of $63.50. The firm has a market cap of $2.63 billion, a price-to-earnings ratio of -13.79 and a beta of 1.43. The company has a fifty day moving average price of $40.60 and a 200-day moving average price of $39.16.

Apogee Therapeutics (NASDAQ:APGE) last posted its earnings results on Monday, August 11th. The company reported ($1.13) earnings per share (EPS) for the quarter, missing the consensus estimate of ($1.03) by ($0.10). On average, research analysts anticipate that Apogee Therapeutics Inc. will post -3.09 EPS for the current fiscal year.

Insiders Place Their Bets

In related news, insider Carl Dambkowski sold 5,110 shares of the stock in a transaction dated Wednesday, October 1st. The shares were sold at an average price of $39.80, for a total transaction of $203,378.00. Following the completion of the transaction, the insider owned 284,733 shares in the company, valued at approximately $11,332,373.40. This represents a 1.76% decrease in their ownership of the stock. The transaction was disclosed in a filing with the Securities & Exchange Commission, which can be accessed through this link. Insiders have sold a total of 10,560 shares of company stock worth $409,524 in the last three months. 42.77% of the stock is currently owned by corporate insiders.

Apogee Therapeutics Company Profile

Apogee Therapeutics, Inc, through its subsidiary, operates as a biotechnology company that develops biologics for the treatment of atopic dermatitis (AD), asthma, chronic obstructive pulmonary disease (COPD), and related inflammatory and immunology indications. The company primarily develops APG777, a subcutaneous (SQ) extended half-life monoclonal antibody (mAb) for AD; and APG808, an SQ extended half-life mAb for COPD.